Helen Torley Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $40,063,244.80. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Helen Torley also recently made the following trade(s):

• On Tuesday, September 10th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00.

Halozyme Therapeutics Trading Up 2.9 %

NASDAQ HALO opened at $62.30 on Friday. The company has a market cap of $7.89 billion, a P/E ratio of 25.74, a P/E/G ratio of 0.57 and a beta of 1.28. Halozyme Therapeutics, Inc. has a 12 month low of $32.83 and a 12 month high of $65.53. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. The company has a 50-day moving average of $57.35 and a 200-day moving average of $48.26.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. Halozyme Therapeutics’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.68 earnings per share. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in HALO. International Assets Investment Management LLC acquired a new stake in Halozyme Therapeutics during the fourth quarter worth about $1,030,000. Private Advisor Group LLC increased its position in Halozyme Therapeutics by 6.2% during the 4th quarter. Private Advisor Group LLC now owns 23,451 shares of the biopharmaceutical company’s stock worth $867,000 after purchasing an additional 1,377 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Halozyme Therapeutics by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,736,122 shares of the biopharmaceutical company’s stock valued at $64,167,000 after buying an additional 37,763 shares during the period. Principal Securities Inc. acquired a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $34,000. Finally, Dimensional Fund Advisors LP grew its stake in Halozyme Therapeutics by 9.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock worth $59,622,000 after buying an additional 145,879 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of recent research reports. The Goldman Sachs Group upped their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Wells Fargo & Company upped their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Morgan Stanley lifted their price objective on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. TD Cowen upped their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $59.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.